RCE · ASX

Recce Pharmaceuticals Ltd. (ASX:RCE)

AU$0.4

 0.005 (1.25%)
ASX:Live
10/10/2025 04:10:04 PM
Recent Earnings downgrade HALO Ords HALO Consensus Value HALO Capital Efficiency GROWTH AUS +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RCE Overview

RCE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Weak

About RCE

Website

Recce Pharmaceuticals Ltd.

Telephone

61.2.9000.1907

Address

Level 15 Governor Macquarie Tower 1 Farrer Place Sydney, New South Wales (NSW) 2000

Description

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.

RCE Price Chart

Key Stats

Market Cap

AU$115.67M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.28 - 0.56

Trade Value (12mth)

AU$15,911.00

1 week

-9.6%

1 month

-9.09%

YTD

-17.58%

1 year

-24.51%

All time high

1.84

Key Fundamentals

EPS 3 yr Growth

46.00%

EBITDA Margin

N/A

Operating Cashflow

-$20m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-21.90

Quick Ratio

1.90

Other Data

Shares on Issue (Fully Dilluted)

242m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.27

RCE Announcements

Latest Announcements

Date Announcements

08 October 25

Update - Notification of buy-back - RCE

×

Update - Notification of buy-back - RCE

08 October 25

Notification of cessation of securities - RCE

×

Notification of cessation of securities - RCE

07 October 25

Update - Notification of buy-back - RCE

×

Update - Notification of buy-back - RCE

03 October 25

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

25 September 25

Patient Dosing Underway in Ph 3 Indonesia DFI Trial

×

Patient Dosing Underway in Ph 3 Indonesia DFI Trial

15 September 25

2025 Annual General Meeting

×

2025 Annual General Meeting

29 August 25

Preliminary Final Report

×

Preliminary Final Report

29 August 25

Annual Report to Shareholders

×

Annual Report to Shareholders

29 August 25

Appendix 4G

×

Appendix 4G

25 August 25

Notification regarding unquoted securities - RCE

×

Notification regarding unquoted securities - RCE

12 August 25

R327G Highly Effective in Burn Wounds Model

×

R327G Highly Effective in Burn Wounds Model

05 August 25

Abstract & Poster Presentation at US Military Symposium 2025

×

Abstract & Poster Presentation at US Military Symposium 2025

31 July 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 July 25

Change in substantial holding

×

Change in substantial holding

14 July 25

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

14 July 25

Cleansing Notice

×

Cleansing Notice

17 June 25

Recce Signs Debt Facility with Avenue Capital Group

×

Recce Signs Debt Facility with Avenue Capital Group

17 June 25

Proposed issue of securities - RCE

×

Proposed issue of securities - RCE

12 June 25

Change in substantial holding

×

Change in substantial holding

11 June 25

Change in substantial holding

×

Change in substantial holding

10 June 25

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

10 June 25

Cleansing Notice

×

Cleansing Notice

06 June 25

Becoming a substantial holder

×

Becoming a substantial holder

03 June 25

Successful Placement of Entitlement Offer Shortfall

×

Successful Placement of Entitlement Offer Shortfall

26 May 25

China Patent Accepted for RECCE Anti-Infectives

×

China Patent Accepted for RECCE Anti-Infectives

RCE Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.10 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.10 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.1 -34.1 8.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.07 -0.08 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.07 -0.07 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -18.5 -21.6 18.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.7 -12.4 -29.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock -0.01 -0.05 -0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.01 -0.05 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -125.6 -224.7 77.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 177 179 237 Lock Lock Lock
Basic m Lock Lock Lock Lock 177 179 237 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 17 22 28 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.7 -68.9 2.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -17 -22 -28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.5 -26.7 -27.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -17 -22 -28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.4 -27.3 -27.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -17 -23 -28 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -4 -5 -7 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -13 -18 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.0 -35.1 -21.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -13 -20 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 3 16 27 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -13 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.6 -3.3 -55.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 4 10 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 3 6 12 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 1 9 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 -4 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 5 16 15 Lock Lock Lock
Equity $m Lock Lock Lock Lock -3 -10 -3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock -2 -9 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -124.7 -259.5 166.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -511.7 -277.3 -172.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 505.2 185.4 702.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -444.4 0.0 0.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -345.3 0.0 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -335.0 0.0 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -93.4 -25.6 -21.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.1 0.2 -0.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 50.6 37.8 -10.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.4 0.3 1.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.4 0.3 1.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 80.2 86.0 91.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -261.6 -86.3 -333.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -511.7 -277.3 -172.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock -1.0 -0.7 -4.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 505.2 185.4 702.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 505.2 185.4 702.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,202.2 2,446.4 3,152.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,202.2 -2,446.4 -3,152.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.08%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RCE Shortsell

Frequently Asked Questions

The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.4.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.56.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.28.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .
The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.4.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.56.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.28.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff